In a new study from Angioskope Brazil, São José dos Campos, researchers found that combining minimally invasive endoscopic sleeve gastroplasty (ESG) with the diabetes drug semaglutide can lead to strong weight loss.
As the worldwide obesity rate continues to climb, so do the number of people seeking bariatric surgery to treat their condition.
Surgical procedures are some of the most successful ways to help patients lose weight, but they can eventually come with complications.
In the study, the team divided 61 patients undergoing ESG into two groups.
One group of 29 patients receiving semaglutide—an injectable drug that has been known to stimulate weight loss—beginning one month after the procedure. Another group of 29 patients received a placebo.
The team found people who received semaglutide lost on average 26.7% of their total body weight compared to the control group, which on average lost 19.6% of total body weight.
The semaglutide group lost 86.3% of their excess weight—the amount of weight the patients needed to lose to reach normal BMI—compared to 60.4% for the control group.
The semaglutide group also lost 12.7%of their body fat by weight compared to 9% for the control group.
Finally, glycated hemoglobin (Hb1Ac) levels fell 0.95 for the semaglutide group and 0.61 for the controls.
The team says surgical procedures, such as laparoscopic sleeve gastrectomy, come with increased costs and a higher risk for complications, such as gastroesophageal reflux disease, or GERD.
These surgical procedures are typically limited to those with a BMI of at least 35 with comorbidities, or with a BMI above 40.
ESG can be performed at an earlier stage of the disease and at a lower BMI, so more patients can get the treatment they need before their disease progresses.
Treating patients with obesity earlier can help reduce death and comorbidities as well as reduce costs associated with treatments for these conditions.
If you care about weight loss, please read studies about this new therapy may be alternative to weight loss surgery and findings of timing of exercise may be key to your weight loss success.
For more information about obesity prevention and treatment, please see recent studies about this eating habit may help lose weight, preventing type 2 diabetes and results about function insertAfter(e, t) {
t.parentNode.insertBefore(e, t.nextSibling)
}
function getElementByXPath(e, t) {
if (!t) t = document;
if (t.evaluate) return t.evaluate(e, document, null, 9, null).singleNodeValue;
while (e.charAt(0) == "/") e = e.substr(1);
var n = t;
var r = e.split("/");
for (var i = 0; i < r.length; i++) {
var a = r[i].split(/(\w*)\[(\d*)\]/gi).filter(function(e) {
return !(e == "" || e.match(/\s/gi))
}, this);
var l = a[0];
var o = a[1] ? a[1] - 1 : 0;
if (i < r.length - 1) n = n.getElementsByTagName(l)[o];
else return n.getElementsByTagName(l)[o]
}
}
if (!Array.prototype.filter) {
Array.prototype.filter = function(e) {
var t = this.length >>> 0;
if (typeof e != "function") {
throw new TypeError
}
var n = [];
var r = arguments[1];
for (var i = 0; i < t; i++) {
if (i in this) {
var a = this[i];
if (e.call(r, a, i, this)) {
n.push(a)
}
}
}
return n
}
}
function injectWidgetByXpath(e) {
var t = getElementByXPath(e);
if (t == null) {
t = document.getElementById("tbdefault")
}
innerInject(t)
}
function injectWidgetByMarker(e) {
var t = document.getElementById(e);
innerInject(t.parentNode)
}
function innerInject(e) {
var t = document.createElement("span");
var n = document.createElement("script");
var r = "if JS crashes here, the first innerHTML value should be enclosed with single quotes instead of double, go to the minified version and change it";
t.innerHTML = "";
n.innerHTML = "window._taboola = window._taboola || [];_taboola.push({mode:'alternating-thumbnails-a', container:'taboola-below-article-thumbnails', placement:'below-article', target_type: 'mix'});";
insertAfter(t, e);
insertAfter(n, t)
}injectWidgetByMarker('tbmarker');
